Reduction in the frequency of hospitalizations, by delaying additional episodes of acute decompensated heart failure; and Weaning patients with severe heart failure who are currently dependent on ...

Toronto, ON - An investigational oral inotropic agent, a selective inhibitor of phosphodiesterase-3 (PDE-3), took a small, uncertain step forward when a randomized, placebo-controlled trial showed it ...

Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the ...

A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...

Please provide your email address to receive an email when new articles are posted on . In the CAPITAL Do-Re-Mi trial, there was no difference in outcomes in patients treated with the widely used ...

Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...

Against expectations, critically ill people in cardiogenic shock fared similarly receiving one widely used inotrope or another in the small DOREMI trial. Patients had the same clinical outcomes on ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

BANNOCKBURN, Ill., May 16, 2018 – Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of ...